Get the Stockscreener App
1.22
1.67%
0.02
Artelo Biosciences Inc stock is traded at $1.22, with a volume of 6,142.
It is up +1.67% in the last 24 hours and down -10.95% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$1.20
Open:
$1.21
24h Volume:
6,142
Relative Volume:
0.01
Market Cap:
$2.55M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.3861
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
-1.61%
1M Performance:
-10.95%
6M Performance:
-72.95%
1Y Performance:
-80.07%
1-Day Range:
$1.1801
$1.2292
1-Week Range:
$1.05
$1.2749
52-Week Range:
$1.05
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.20 | 2.55M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.36 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.71 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
ARTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ARTL SEC FilingsArtelo Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ARTL PE Ratio & Valuation, Is ARTL Overvalued - Intellectia AI
Artelo Biosciences, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Artelo Biosciences (ARTL) Reports Key Advances and Financial Res - GuruFocus
Artelo Biosciences reports $12.9M loss for 2025 - Investing.com South Africa
ARTL: Strong clinical advances offset by higher net loss and lower cash reserves in 2025 - TradingView
Artelo Biosciences (NASDAQ: ARTL) outlines oncology and neuropathy drug pipeline - Stock Titan
ARTL: Net loss increased to $12.9 million in 2025, with urgent need for new funding to sustain operations - TradingView
Artelo Biosciences Provides Business Update Highlighting - GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Cancer appetite, pain and depression drugs: Artelo’s 2025 trial gains - Stock Titan
Artelo Biosciences (NASDAQ:ARTL) Trading Down 6.1% – What’s Next? - Defense World
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results - Bitget
Can Artelo Biosciences Inc. continue delivering strong returnsWeekly Investment Report & Entry Point Confirmation Alerts - mfd.ru
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
D. Boral Capital Upgrades Artelo Biosciences (ARTL) - MSN
Artelo Biosciences Granted Nasdaq Extension to Regain Compliance - The Globe and Mail
Artelo Biosciences Secures Flexible Multiyear Equity Financing - TipRanks
Artelo Biosciences Granted Nasdaq Compliance Extension - TradingView
Trade Recap: Is The TJX Companies Inc affected by consumer sentiment2025 Price Momentum & Weekly Top Performers Watchlists - baoquankhu1.vn
Artelo Biosciences Stockholders Approve Directors, Say-on-Pay and Auditor at 2025 Annual Meeting - Defense World
Why analysts upgrade Artelo Biosciences Inc. stockPortfolio Profit Report & AI Driven Stock Movement Reports - mfd.ru
Artelo Biosciences, Inc. (NASDAQ:ARTL) Given Average Rating of “Hold” by Brokerages - Defense World
ARTL: All proposals passed, with directors re-elected and no shareholder questions submitted - TradingView
Stock Analysis: Is Artelo Biosciences Inc impacted by rising ratesWeekly Trade Review & Accurate Intraday Trading Signals - baoquankhu1.vn
Can Constellation Brands Inc lead its sector in growthWeekly Risk Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Artelo Biosciences adjourns and reschedules 2025 annual meeting - MSN
Market Leaders: Is KORE attractive at current valuationJuly 2025 Outlook & Reliable Trade Execution Plans - baoquankhu1.vn
Artelo Biosciences faces new Nasdaq compliance challenges - The Globe and Mail
Artelo Biosciences Received Notice of Noncompliance - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
How Artelo Biosciences Inc. stock reacts to inflationary pressuresDaily Trainer Picks & support options for steady strides - ulpravda.ru
Artelo Biosciences, Inc.Common Stock (NQ: ARTL - FinancialContent
D. Boral Capital Downgrades Artelo Biosciences (ARTL) - MSN
What makes Inno Holdings Inc. stock price move sharply - ulpravda.ru
Can Artelo Biosciences Inc. stock sustain free cash flow growthTrade Volume Report & Free Community Consensus Stock Picks - ulpravda.ru
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Is Artelo Biosciences Inc. stock a buy in volatile marketsJuly 2025 Technicals & Growth Focused Entry Point Reports - Улправда
Star TribuneArtelo Biosciences, Inc.Common Stock (Nasdaq:ARTL) Stock Quote - FinancialContent
How strong is Artelo Biosciences Inc. stock balance sheetCPI Data & Capital Protection Trading Alerts - ulpravda.ru
Artelo Biosciences Inc Stock Analysis and ForecastCandlestick Trading Patterns & Best Stocks For Explosive Growth - earlytimes.in
Artelo Biosciences, Inc. (NASDAQ:ARTL) Given Average Recommendation of “Hold” by Analysts - Defense World
Bank Watch: Can Artelo Biosciences Inc stock deliver 10 annual returnsQuarterly Market Summary & Reliable Price Breakout Alerts - moha.gov.vn
Is Artelo Biosciences Inc a good long term investmentAI-Driven Market Analysis & Explosive Growth Opportunities - earlytimes.in
Artelo Biosciences adjourns annual meeting due to lack of quorum - Investing.com
Artelo Biosciences Adjourns and Reschedules 2025 Annual Meeting - TipRanks
Artelo Biosciences adjourns annual meeting due to lack of quorum By Investing.com - Investing.com South Africa
Artelo Biosciences Adjourns and Reschedules Annual Meeting - TradingView — Track All Markets
Technical Analysis: How strong is Artelo Biosciences Inc stock balance sheetQuarterly Profit Report & Scalable Portfolio Growth Ideas - Bộ Nội Vụ
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):